Innoviva, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2019. Innoviva is a royalty-management company whose revenue is primarily royalties on GSK respiratory products: RELVAR/BREO ELLIPTA, ANORO ELLIPTA and TRELEGY ELLIPTA.
Financial performance
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Net royalty revenue | $64.1 million | $67.1 million | $119.3 million | $119.5 million |
| Operating income | $59.8 million | $62.7 million | $111.9 million | $103.4 million |
| Income before taxes | $56.5 million | $56.6 million | $105.0 million | $86.9 million |
| Net income | $46.1 million | $56.6 million | $86.1 million | $86.9 million |
| Net income attributable to Innoviva | $37.7 million | $54.6 million | $71.5 million | $84.2 million |
| Diluted EPS attributable to Innoviva | $0.34 | $0.49 | $0.65 | $0.77 |
- Q2 operating margin was approximately 93% of net royalty revenue. The filing does not present a separate margin measure.
- Q2 2019 income tax expense was $10.4 million; first-half expense was $18.9 million, versus immaterial amounts in 2018. The six-month effective tax rate was 18%.
- Interest expense was $4.7 million for Q2 and $9.3 million for the first half, down 28% and 34%, respectively, year over year. Higher cash and investment balances lifted first-half interest income to $2.4 million from $0.8 million.
- Operating cash flow for the first half was $133.2 million, up from $101.6 million. Investing cash flow was negative $54.1 million, principally reflecting purchases of marketable securities; financing cash flow was positive $0.4 million. Cash increased $79.5 million to $142.0 million.
Financial position and liquidity
- At June 30, 2019, cash and cash equivalents were $142.0 million and short-term marketable securities were $107.7 million, totaling $249.7 million. Related-party royalty receivables were $67.6 million.
- Total assets were $642.3 million; stockholders’ equity was $246.7 million, including $20.0 million of noncontrolling interest.
- Debt principal totaled $447.2 million: $13.8 million Term B Loan, $241.0 million 2023 Notes and $192.5 million 2025 Notes. Net carrying value was $386.7 million. The filing reports debt fair value of $474.7 million.
- Scheduled principal maturities include $13.8 million in 2022 and $241.0 million in 2023; the 2025 Notes principal is $192.5 million. The Term B Loan bears interest at three-month LIBOR plus 4.5%.
- Management said cash, investments and projected royalty receipts should meet anticipated debt-service and operating needs for at least the next 12 months, based on current plans and forecasts.
Material changes and business developments
- Q2 net royalty revenue decreased 4% year over year. RELVAR/BREO royalties fell 18% to $47.1 million, primarily amid U.S. pricing pressure; ANORO royalties were essentially flat at $10.6 million; TRELEGY royalties rose to $9.8 million from $2.4 million.
- GSK-reported Q2 product sales were $313.9 million for RELVAR/BREO, down 18%; $163.6 million for ANORO, approximately flat; and $151.4 million for TRELEGY, up from $36.5 million.
- For the first half, G&A expense declined to $7.4 million from $16.1 million. The 2018 comparator included $3.2 million of severance and a $2.7 million payment to Sarissa Capital for expense reimbursement.
- The higher share of net income allocated to noncontrolling interest reflects Theravance Biopharma’s 85% economic interest in TRC; that allocation rose to $8.3 million in Q2 and $14.6 million in the first half, primarily alongside TRELEGY growth.
Outlook, risks and unusual items
- No specific revenue, earnings or product-sales guidance was provided. Management’s liquidity outlook is conditional on current operating plans and financial forecasts; additional financing could be needed if those change, and financing may not be available on acceptable terms.
- Theravance Biopharma initiated arbitration in May 2019 against Innoviva and TRC concerning Innoviva’s decision, as TRC manager, to explore reinvestment of royalty proceeds rather than distribute substantially all proceeds. The claimant alleges breach of the operating agreement and fiduciary duties and seeks material damages. The hearing began July 23, 2019; Innoviva disputes the allegations and says the outcome is uncertain.
- Innoviva guarantees certain Theravance Biopharma facility lease obligations if that company defaults. Remaining lease payments through May 2020 were $6.0 million; the recorded guarantee liability was $0.3 million.
- The company adopted lease accounting effective January 1, 2019, recognizing a $1.5 million right-of-use asset and $1.6 million lease liabilities for its headquarters; management said the adoption did not materially affect earnings or cash flows.
- Management identified risks including lower-than-expected GSK royalties, product commercialization and pricing, and execution of growth, corporate-development and capital-return plans. Disclosure controls were assessed as effective; no material change in internal control was reported.
Key facts for investors to verify
- Whether GSK product sales and royalty trends—especially RELVAR/BREO pricing pressure and TRELEGY’s rapid growth—persist in subsequent periods.
- The arbitration outcome, potential damages, and whether TRC royalty proceeds are distributed or reinvested.
- Debt service, upcoming maturities and the assumptions supporting management’s 12-month liquidity assessment.
- The effect of taxes and TRC noncontrolling-interest allocations on earnings attributable to Innoviva shareholders.